InMed Pharmaceuticals Inc.
Company Information
Industry
Pharmaceutical Preparations
SIC Code
2834
Entity Type
operating
SEC Category
Emerging growth company
State of Incorporation
British Columbia, Canada
Business Address
1445-885 WEST GEORGIA ST., VANCOUVER, A1, V6C 3E8
Mailing Address
1445-885 WEST GEORGIA ST., VANCOUVER, A1, V6C 3E8
Phone
(604) 669-7207
Fiscal Year End
0630
EIN
000000000
Recent SEC Filings
| Form Type | Date Filed | Document |
|---|---|---|
| 8-K Current report of material events | April 3, 2026 | View on SEC |
| 424B5 Prospectus supplement | April 3, 2026 | View on SEC |
| 8-K Current report of material events | March 30, 2026 | View on SEC |
| 8-K Current report of material events | March 23, 2026 | View on SEC |
| S-3 Shelf registration for future offerings | March 20, 2026 | View on SEC |
| 8-K Current report of material events | March 9, 2026 | View on SEC |
| 8-K Current report of material events | March 6, 2026 | View on SEC |
| 8-K Current report of material events | February 12, 2026 | View on SEC |
| 10-Q Quarterly financial report | February 11, 2026 | View on SEC |
| SCHEDULE 13G Passive beneficial ownership (>5%) | January 20, 2026 | View on SEC |
Annual Reports
10-K
September 23, 2025
- First-ever Phase 2 trial for cannabinol drug INM-755 (EB) showed safety and hinted at efficacy.
- Preclinical Alzheimer’s drug INM-901 demonstrates potential to target brain inflammation.
Material Events
8-K
Financial Distress
March 30, 2026
High Impact
- Active development of clinical-stage drug candidates INM-901 and INM-755
- Company remains fully operational with no disruption to clinical trials
8-K
Strategy Change
March 6, 2026
High Impact
- Complete pivot to high-potential pharmaceutical drug development.
- Advancing two promising drug candidates: INM-901 (Alzheimer's) and INM-089 (Dry AMD).
8-K
Legal Issue
December 15, 2025
High Impact
- InMed Pharmaceuticals announced a potential "material negative impact" on its subsidiary, BayMedica Inc., due to new U.S. law H.R. 5371.
- The law, set to come into force on November 12, 2026, would prohibit certain aspects of BayMedica’s commercial business and its inventory of rare, non-intoxicating cannabinoids.
Related Companies
Companies in the same industry (SIC: 2834)
Investor Resources
Learn more about SEC filings and how to research public companies.
What is the SEC?
A plain English guide to the Securities and Exchange Commission
Understanding SEC Filings & CIK
How to navigate SEC filings and Central Index Keys
10-K Annual Reports Explained
Everything you need to know about annual reports
S-1 & F-1 IPO Filings
Understanding IPO registration statements
SEC EDGAR Database Guide
How to use the SEC's free filing database
Important Disclaimer
This AI-generated analysis is for informational purposes only and does not constitute financial or investment advice. Always consult with qualified professionals and conduct your own research before making investment decisions.